Prostate cancer refers to an epithelial malignant tumor that occurs in the prostate. The 2004 WHO "Pathology and Genetics of Tumors of Urinary System and Male Reproductive Organs" included adenocarcinoma (acinar adenocarcinoma), ductal adenocarcinoma, urothelial carcinoma, squamous cell carcinoma, and adenosquamous carcinoma in the pathological types of prostate cancer. . Among them, prostate adenocarcinoma accounts for more than 95%. Therefore, usually what we call prostate cancer refers to prostate adenocarcinoma. In 2012, the incidence of prostate cancer in my country's tumor registration areas was 9.92 per 100,000, ranking sixth in the incidence of male malignant tumors. The age of onset is at a low level before 55 years old, and gradually increases after 55 years of age. The incidence rate increases with age, and the peak age is 70 to 80 years. The age of onset of familial prostate cancer is earlier, and 43% of patients are younger than 55 years old.
Thin urine line, short range, slow urine flow, interrupted urine flow
Interruption of urine flow, dripping after urine, incomplete urination, and laborious urination
Frequent urination, urgency, increased nocturia, and even urinary incontinence
Hematuria, blood sperm, impotence
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:
1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.
2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.
3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108
4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.
5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;
2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
